Research programme: plasmin inhibitor - Shire

Drug Profile

Research programme: plasmin inhibitor - Shire

Alternative Names: 4PEG-DX-1000; 4PEG5-DX-1000; DX-1000; EPI-PLA; PEGylated DX-1000

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator Dyax
  • Developer Shire
  • Class Antineoplastics
  • Mechanism of Action Diagnostic imaging enhancers; Plasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 07 Dec 2006 No development reported - Preclinical for Cancer diagnosis in USA (unspecified route)
  • 07 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top